Medical oxygen innovation landscape
Women’s and children’s health
Unitaid audited financial report for the year ended 31 December 2023
The untold story of dolutegravir: When climate impact goes hand-in-hand with access to better treatments
Antimalarial manufacturing in Africa: A call for regional action
Unitaid’s climate and health strategy 2023-2027
Unitaid’s investment case 2023-2027, executive summary
Unitaid’s investment case 2023-2027
Unitaid Strategy 2023-2027
Maternal and newborn health
Women’s and children’s health
Biomarkers for acute febrile illness at the point-of-care in low-resource settings. Meeting report
Accelerating access to innovative point-of-care HIV diagnostics: Lessons learned from UNICEF
Innovative delivery systems for paediatric medicines technology landscape
Disease Narrative for hepatitis C
Disease narrative for tuberculosis
Disease Narrative for malaria
Disease Narrative for HIV
Hepatitis C diagnostics technology landscape – May 2019
Unitaid and the Government of Spain
About Unitaid (Saving lives faster)
Unitaid and the UK Government
Unitaid audited financial report for the year ended 31 December 2023
Partnership report: Unitaid and the Global Fund to Fight AIDS, Tuberculosis and Malaria
Unitaid audited financial report for the year ended 31 December 2022
Patent landscape: grazoprevir
Patent landscape: elbasvir
Patents and licenses on antiretrovirals: a snapshot
Malaria medicines technology and market landscape – 2nd edition
Malaria diagnostics market landscape – semi-annual update
Hepatitis C medicines technology and market landscape
Hepatitis C diagnostics technology landscape – 1st edition
HIV/AIDS diagnostics technology landscape – semi-annual update
